Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia

BACKGROUND: Visceral leishmaniasis (VL) is one of the most neglected tropical infectious diseases. It is fatal if left untreated. The objective of this study was to assess the efficacy and safety of 17-day injections of combined regimen of sodium stibogluconate and paromomycin (SSG/PM) in HIV-negati...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamiru, Aschalew, Mohammed, Rezika, Atnafu, Saba, Medhin, Girmay, Hailu, Asrat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437273/
https://www.ncbi.nlm.nih.gov/pubmed/34464401
http://dx.doi.org/10.1371/journal.pntd.0009713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437273/
https://www.ncbi.nlm.nih.gov/pubmed/34464401
http://dx.doi.org/10.1371/journal.pntd.0009713

Ejemplares similares